Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Sahil Sharma

Research Fellow

 

I received my PhD in Pharmaceutical Chemistry from Guru Nanak Dev University, Amritsar, Punjab, India. My doctoral thesis described the design and synthesis of heterocyclic molecules with antitubulin and xanthine oxidase inhibitory activity that can be useful in cancer and gout, respectively. These compounds were rationally designed using molecular hybridization approach based on the combination of pharmacophoric moieties of different bioactive substances to produce a new hybrid compound with improved affinity and efficacy. An extensive library of compounds were synthesized and evaluated in a number of in vitro assays designed to measure antitubulin activity and inhibition of xanthine oxidase. These results led to establishment of structure activity relationship within azacarboline and naphthopyran class of compounds as tubulin and xanthine oxidase inhibitors, which were further rationalized by molecular modeling studies.


Currently, I am working as a postdoctoral research fellow in the laboratory of Dr. Gabriela Chiosis at MSKCC.  Broadly speaking, my research involves the rational development of probes that selectively target Hsp90 networks, which are present as multi-chaperone complexes in cancer cells and play a critical role in the development of cancer and potentially other diseases. One of the aims of my project is to develop fluorescent probes that target oncogenic Hsp90 networks and can be used for intraoperative visualization of cancer cells during surgical procedures. Since, surgical removal of operable tumors remains the gold standard care in the treatment of many tumors, a method for the detection of the extent of malignancy is key for an optimal surgical outcome and to reduce surgery related complications.

Publications


  1. Ojha, R.; Singh, J.; Ojha, A.; Sigh, H.; Sharma, S.*; Nepali, K. Xanthine Oxidase Inhibtors for the treatment of Hyperuricemia and gout An updated patent review. Expert Opin Ther Pat 2017, 27, 311-345.

  2. Kaur, M.; Kaur, A.; Mankotia, S.; Singh, H.; Singh, A.; Singh, J. V.; Gupta, M. K.; Sharma, S.*; Nepali, K.; Bedi, P. M. S. Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor. Eur J Med Chem. 2017, 131, 14-28.

  3. Sharma, S.*; Gupta, M. K.; Saxena A. K.; Bedi, P. M. S. Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies. Anticancer Agents Med Chem. 2017, 17, 230-240.

  4. Singh, H.; Singh, J. V.; Gupta, M. K.; Singh, P.; Sharma, S.*; Nepali, K.; Bedi ,P. M. S. Benzoflavones as cholesterol esterase inhibitors: Synthesis, biological evaluation and docking studies. Bioorg Med Chem Lett. 2017, 27, 850-854.

  5. Sharma, S.; Ojha, R.; Singh, H.; Nepali, K. Design Strategies, Structure Activity Relationship and Mechanistic Insights for Purines as Kinase Inhibitors. Eur J Med Chem 2016, 112, 298-346.

  6. Singh, H.; Kumar, M.; Nepali, K.; Gupta, M. K.; Saxena, A. K.; Sharma, S.*; Bedi, P. M. S. Triazole tethered C5-curcuminoid-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Eur J Med Chem 2016, 116, 102-115.

  7. Singh, A,; Kaur, N.; Singh, G.;  Sharma, P.; Bedi, P.; Sharma, S.*; Nepali, K.;Topoisomerase I and II Inhibitors: A Patent Review. Recent Pat Anticancer Drug Discov 2016, 11, 401-423.

  8. Sharma, S.*; Gupta, M. K.; Saxena, A. K.; Bedi, P. M. S. Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: Design, synthesis, biological evaluation and molecular modeling studies. Bioorg Med Chem 2015, 23, 7165-7180.

  9. Sharma, S.; Mehndiratta, S.; Yadav, S.; Bedi, P. M. S.; Nepali, K. Purine Analogues as Kinase Inhibitors: A Review. Recent Pat Anticancer Drug Discov 2015, 10, 308-341.

  10. Kaur, M.; Sharma, S.*; Bedi, P. M. S. Silica supported Brӧnsted acids as catalyst in organic transformations: A comprehensive review. Chinese J Catal 2015, 36, 520–549.

  11. Singh, H.; Singh, H.; Sharma, S.*; Bedi, P. M. S. Chemotherapeutic potential of acridine analogs: An ample review. Heterocycles 2015, 91, 2043-2085.

  12. Sharma, S.; Kaur, C.; Budhiraja, A.; Nepali, K.; Gupta, M. K.; Saxena, A. K.; Bedi, P. M. S. Chalcone based azacarboline analogues as novel antitubulin agents: Design, synthesis, biological evaluation and molecular modeling studies. Eur J Med Chem 2014, 85, 648-660.

  13. Sharma, S.; Sharma, K.; Ojha, R.; Kumar, D.; Singh, G.; Nepali ,K.;  Bedi ,P. M. S. Microwave assisted synthesis of naphthopyrans catalysed by silica supported fluoroboric acid as a new class of non purine xanthine oxidase inhibitors. Bioorg Med Chem Lett 2014, 24, 495–500.

  14. Sharma, S.; Thakur, V.; Ojha, R.; Budhiraja, A.; Nepali, K.; Bedi, P. M. S. Aza Analogs of Flavones as Potential Antimicrobial Agents. Lett Drug Des Discov 2013, 10, 327-334.